FDA has expressed concern over improper use of Duragesic first generation fentanyl patch product. Janssen is expected to issue a "Dear Doctor" letter to remind medical community of labeled indications. Among current label restrictions is a statement that the product is not recommended for treatment of post-op pain. As Janssen prepares to clarify current product usage, Alza reports to securities analysts on Jan. 13 that the two companies are in clinical trials with a fentanyl product using Alza's electrotransport technology. The new product "will allow a patient to titrate the level of required opioid input to alleviate severe pain through the use of a self-adhesive, disposable, transdermal system." The second generation product is designed for the acute pain market, Alza says...
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth